justment was not performed(p < 0.05).The same associationwas found when the clinicalrelevanceof the dosage adjustmentwas moderatelysevere or severe (Table 1) .
Early Identification of Long-Term Poor Adherence in Ambulatory Patients TOTHEEDITOR: Poor adherence leads to poor disease control and increasedcosts.' Earlyidentification of patientsat riskfor long-term poor adherence is therefore important.We investigated whetherearly identification of patientsat risk for long-termpoor adherenceis possiblein a community pharmacy setting by performing a case-control study that consisted of a groupof patients receiving drug therapyforat leastone year. Methods. Themedication possession ratio (MPR), calculated bydividing cumulative days ofdrug supply bytotal number of days intheinterval in which the drug was obtained, wasusedas a proxy for nonadherence," Cases were patients with an MPR of 80% or lessintheyearfollowing thesixth dispensing of a drug; controls were allother patients within thestudy population. We recalculated MPR oneyear after thesixth dispensing toensure independence ofthedata forthefirst 5 refills from theoneyear adherence data. Themain determinant was MPRat fills 2 (average 43days), 3(\03),4 (161), and5 (222). Other predictors were patient age, number ofprescriptions inoneyear, andtotal number ofdrugs used between fills I and 5. We didnotinclude number of daily doses as a possible predictor dueto changes indosing frequencies overtime. A multivariate logistic regression model wasused to assign a riskscore, with theregression coefficient multiplied by \0 androunded tothenearest integer as thescore foreachpredictor variable. Total risk scores (sum ofallindividual predictors) were calculated foreach patient.
Results. From 3845 patients who received new prescriptions during the study period, we identified606 (16%) cases and 3239 controls.Average age of patientswas 67.1 years, and 41.7% were male. Averagenumber of different medications being taken was 11.7 per patient between fills 1 and 6. Overall nonadherence in our study was low (16%) compared with the percentage in other studies (as high as 50%'), probably becausewe includedonly patientswho were persistentfor over one year, thus excluding initial nonadherencethat is frequentlypresent in patients who discontinuedrug therapy prematurely.' Table 1 shows adjusted regression coefficients and individual risk scores for each predictor includedat the third fill. Poor MPR at that time (MPR-3)and a drug regimenof no more than 30 prescriptions per person werethe strongest predictors of nonadherence. The type of drughad no effecton adherence. The maximum total riskscorewas 28.sensitivityat a total riskscoregreaterthanor equalto 17was 35% and specificity was87%.
Old age and a drug regimenconsistingof fewer medicationshave previouslybeen associatedwith poor drug adherence.v If we choose a cut-off total risk value of at least 17, our model improves efficiency in identifying nonadherence from 16% to 35%. This means that an adherenceimprovement strategydirectedat the total populationof this studycould theoretically be usefulfor 16%of patients,while the same strategy could be applicableto 35% of patients when using our model. The number needed to screen is therefore 5.2 (11[0.35-0.16]), meaningthat we wouldhave to screen52 cases with our modelto identify one who was poorlyadherent.
Our model has limitations.For example, we do not know the proportion of delayedrefillsdue to a patient'shospitalization or inabilityto visit Angiotensin.Converting EnzymeInhibitorsfor Bevacizumab-Induced Hypertension TOTHE EDITOR: Bevacizumab has been used as antiangiogenic therapy for a varietyof tumorsinc!uding renalcell carcinoma, colorectal carcinoma, and breastcarcinoma. Studieswith bevacizumab, a recombinant human monoclonal antilxxiy to vascular endothelial growthfactor(VEGF), have demonstrated that inhibitionof VEGF inducesor exacerbateshy-pertension in some patients.'Grade 3 hypertension has been reportedin 11-28%of patientsreceiving bevacizumab. Hypertension also occurred morefrequently in patients who received higherdosages(eg, 10 mglkg).
Currently,there is no specific antihypertensiveagent recommended for bevacizumab-induced hypertension. However, drugs usedsuccessfully for treatmentof the hypertension includeangiotensin-converting enzyme (ACE)inhibitors and calcium-channel blockers.'
Several studies have demonstrated a hypotensive effect of VEGF. VEGFpreferentially dilatesarterioles and venules withoutany effecton medium-sized arteriesand veins. Intravenous infusionsof recombinant humanVEGF have produced decreases in systolic bloodpressure in humans.This suggested hypotensive effectof VEGFis related to activation of proteinkinaseB, whichstimulates the phosphorylation of endothelial type nitric oxide synthase(eNOS),resulting in augmented,calcium-independentactivityand leadingto enhanced nitric oxide production and hypotension? Furthermore,long-term inhibitionof eNOS is known to induce hypertension.This inhibitionalso increasesexpression of plasminogen activator inhibitor-l (PAl-I) in tissues,' PAl-I, a memberof the serpin superfamily of serine protease inhibitors, serves as the primary physiological inhibitorof tissue plasminogen activator.In other words, plasmaPAl-I is a critical determinant of endogenous fibrinolytic activity and resistanceto thrombolysis.'Therefore, increasedplasma PAl-I activity induced by bevacizumab may also contribute to exacerbationof existinghypertension.
ACE inhibitorsblock the enzyme responsiblefor conversionof biologically inert angiotensin I from activating angiotensin II and block degradation of kinins.Additionally, ACE inhibitors act as antihypertensiveagents,preventing PAI-l expression.'Otherantihypertensive agents, includingcalcium-channel blockers,do not have such an antihypertensive mechanism. Therefore,the useof ACE inhibitors in the treatment of bevacizumab-induced hypertension may be more rational. Moreover, VEGFmaintains the glomerular and peritubular capillary network in the kidneys and may playa role in maintaining the podocyte function as well as renal vasculature,thereby protectingglomeruliand interstitium from progressiverenal insults," The anti-VEGFmoleculebevacizumab may distortthe glomerular and peritubular capillary network, resulting in proteinuria,a rare adverseeffect of bevacizumab. Besides their antihypertensive mechanism of inhibiting PAI-l synthesis, ACE inhibitors may also decrease proteinuria inducedby bevacizumabby changingthe expression and distribution of the important podocyte molecules in nephrons.
In summary, through its VEGF inhibition, bevacizumab decreases eNOS activity,stimulates PAl-I expression, and alters renal podocyte function and renal vasculature. All of these changes increasethe risk of hypertension, proteinuria, hypercoagulopathy, and arterial thrombosis. In contrast, ACE inhibitors, in addition to their primary antihypertensive activity,may also prevent arterial thrombosisby loweringserum PAl-I levelsand bevacizumab-induced proteinuria. Therefore,ACE inhibitors may be the preferred antihypertensive agent in the management of bevacizumab-induced hypertension.
